SAN DIEGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today reported updated data from a pivotal trial of single-agent ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011 in San Diego, CA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in ALCL.
